[The empirical study of Maxingganshi decoction and its compatibility in acute lung injury rats].
OBJECTIVE
To explore the pharmacodyniamic action and the mechanism of action of the Maxingganshi decoction in acute lung injury rats in order to supply the pharmacology evidence to cure the SIRS-ALI of Maxingganshi decoction.


METHODS
The study designed by orthogonal design. The SIRS-ALI model were Conseructed by the LPS intravenous injection and the effects of Maxingganshi decoction and it's different compatibilities to the SIRS-ALI model were observed. The experiments results were analvsised in order to reveal the compatibility rules of the Maxingganshi decocotion.


RESULTS
Maxingganshi decocotion and its different compatibilities had good effects of prevention and cure the SIRS-ALI. The mechanism maybe concerned with the Maxingganshi decocotion can decrease the TNF-alpha and increase the IL-10. The experiments results also indicated that the action of the full formula was the best. The principal drug was the most important in the formula.


CONCLUSIONS
Maxingganshitang has a good effect in anti the ALI; the results indicat that the principal drug is the predominant therapeutic action in the formula ministerial drug. Adjuvant drug and messenger drug can strengthen pharmacodynamic action.
Wang
Wei-guang
WG
Guangdong Provincial Health Care Hospital for Women and Children, Guangzhou 510010, China.
Shi
Xu-guang
XG
Zhai
Li-xiang
LX
Wang
Pei-jian
PJ
Peng
Xiu-feng
XF
Xu
Yu-ying
YY
D000208:Acute Disease; D000818:Animals; D002199:Capillary Permeability / Q000187:drug effects; D004195:Disease Models, Animal; D004338:Drug Combinations; D004365:Drugs, Chinese Herbal / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D016753:Interleukin-10 / Q000097:blood; D008171:Lung Diseases / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D010946:Plants, Medicinal / Q000737:chemistry*; D011654:Pulmonary Edema / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018746:Systemic Inflammatory Response Syndrome / Q000097:blood / Q000188:drug therapy / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
D004338:Drug Combinations; D004365:Drugs, Chinese Herbal; D014409:Tumor Necrosis Factor-alpha; C530196:maxingganshi; D016753:Interleukin-10